patient's own lymphocytes that have been grown in culture and stimulated by the presence of tumour-specific antigen.
(3) Injection of lymphokines produced by lymphocytes in culture grown in the presence of antigen, e.g. transfer factor, or specific macrophageactivating factor. (4) If it is confirmed that humoral factors do in fact produce enhancement in human subjects, then an attempt to alter the balance of cellular to humoral factors may improve the outcome of treatment. This might be achieved by plasmaphoresis, or by splenectomy. (5) By coupling cytotoxic agents to specific antibodies, it might be possible to achieve homing of the cytotoxic agents to the tumour cells alone.
Available evidence today would suggest that the immune mechanisms involved in response to cancer are at the best extremely weak and able to cope with only a relatively small number of malignant cells. If this is confirmed, then perhaps the correct place for immunotherapy would be as part of a combined programme similar to that being developed in the treatment of leukemia. Surgical ablation of the primary tumour in the breast and any grossly involved axillary lymph nodes might be followed up by chemotherapy, which would reduce the number of disseminated malignant cells to the order of magnitude that host defence mechanisms, stimulated in the ways described, could cope with. Mr John Hayward (London): Why does Mr Baum advocate simple mastectomy even in patients with obviously involved axillary nodes? Mr M Baum (Cardiff): Simple mastectomy has never been shown to be inferior to radical mastectomy. Gross, in Philadelphia, carried out simple mastectomy before Halsted performed his radical mastectomies and had identical figures for 10-year survival. It is rare to have axiliary lymph node involvement without evidence of further spread. Only about 12 % of patients have nodal involvement which represents the sole extramammary spread of the disease. There is no evidence that nodal deposits act as a source of distant metastasis. We may be doing patients a disservice by removing lymph nodes which may have some immunoprotective effect. This effect may be a special function of regional lymph nodes. Mr T Hamilton (Edinburgh): The word 'immunotherapy' should be removed from use until 1980. There is no evidence that immunotherapy has any beneficial effect.
Dr M Lederman (Royal Marsden Hospital): I wish to stress the dangers of leaving lymph nodes untreated when involved with tumour. I am pessimistic about the prospects of nontreatment of involved regional lymph nodes. Professor P Alexander (Chester Beatty Research Institute, London): Mr Baum has given a balanced account of the current situation regarding the immune response in breast cancer, but I agree with Mr Hamilton that 'immunotherapy' is a word ahead of its time. There is no evidence, based on properly conducted clinical trials, that 'immunotherapy' applied to solid tumours has a beneficial effect. The question whether immunological manipulations have a role in treatment of breast cancer has yet to be answered; carefully controlled trials are required. The immune responses of the body can only cope with a small number of tumour cells. Extensive tumour bulk effectively neutralizes the body's resistance against the tumour and every effort must, therefore, be made to remove tumour. Hence, I do not agree with involved lymph nodes being left untreated as there is no reason to suppose that they are effective in providing immune reactions directed against the tumour.
Nonspecific stimulation of the immune response as the only form of treatment is of questionable value; it is only marginally effective in the experimental animal. Good clinical studies have shown that BCG treatment had no effect on remission length in acute lymphoblastic leukamia. Finally, there is no evidence that the reticuloendothelial system is stimulated in man by the doses of BCG that are usually given. I suggest that for the present we should continue to use the methods known to be effective in reducing tumour bulk, but that chemotherapy be used in doses which upset the immune mechanism as little as possible.
Pulsed chemotherapy seems to be desirable from this point of view. 'Immunotherapy' should only be given as part of controlled clinical trials and not haphazardly to individual patients, since it may do harm. Professor Sir David Sniithers (Royal Marsden Hospital): Real progress has been made recently with many tumours but in mammary cancer a 'new look' is needed. With modern techniques, diagnosis can now be made earlier than hitherto and this improvement should continue. Perhaps, however, we are detecting only the more favourable tumours by these newer techniques. A close look is also needed into the cost effectiveness of screening, from the points of view of manpower, expense and also whether increased survival is being obtained by earlier detection.
Endocrine therapy seems to have made no great progress recently, but the discovery of substances such as the anticestrogens may be a favourable pointer for the future.
Cytotoxic chemotherapy can sometimes produce dramatic remissions, but the definitions of tumour regression used leave much to be desired. Regression should mean complete disappearance of all detectable tumour in the patient for some months at least.
When different methods of therapy are combined, progress seems to be made. Greater use of combinations of surgery, radiotherapy, endocrine treatment and chemotherapy should be tested. Immunotherapy is still no more than an exciting prospect, but worth pursuing.
